Estrella Immunopharma, Inc. (ESLAW) stock
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.03 (-28.82%)
Close on Nov 17, 2026Market cap $16.53MP/E –Yield –
Estrella Immunopharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Estrella Immunopharma's enterprise value was $21.42M on Nov 11, 2026, against $73.08M a year earlier. Over the last 5 years it ranged from $1.79M to $84.43M, with a median of $25.12M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $21.42M | -59.5% |
| 2025 | Dec 31, 2025 | $52.95M | +33.1% |
| 2024 | Dec 31, 2024 | $39.77M | +134.8% |
| 2023 | Dec 29, 2023 | $16.94M | +19.9% |
| 2022 | Dec 30, 2022 | $14.13M | +6.3% |
| 2021 | Dec 31, 2021 | $13.30M | – |
See a number that looks wrong?